Aspire Biopharma Holdings, Inc.
ASBP
$8.87
-$0.38-4.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 63.10K | 28.40K | 4.30K | 1.90K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 63.10K | 28.40K | 4.30K | 1.90K | -- |
| Cost of Revenue | 93.20K | 22.60K | 5.30K | 1.10K | -- |
| Gross Profit | -30.10K | 5.80K | -1.00K | 900.00 | -- |
| SG&A Expenses | 2.19M | 1.34M | 1.75M | 938.50K | 447.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.51M | 1.66M | 1.85M | 1.15M | 799.90K |
| Operating Income | -2.45M | -1.63M | -1.85M | -1.15M | -799.90K |
| Income Before Tax | -1.27M | -3.22M | -4.71M | -1.85M | -1.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.27M | -3.22M | -4.71M | -1.85M | -1.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.27M | -3.22M | -4.71M | -1.85M | -1.98M |
| EBIT | -2.45M | -1.63M | -1.85M | -1.15M | -799.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.22 | -20.57 | -55.27 | -44.84 | -48.19 |
| Normalized Basic EPS | -1.44 | -11.85 | -34.54 | -28.02 | -24.59 |
| EPS Diluted | -1.22 | -20.57 | -55.27 | -44.84 | -48.19 |
| Normalized Diluted EPS | -1.44 | -11.85 | -34.54 | -28.02 | -24.59 |
| Average Basic Shares Outstanding | 1.04M | 156.70K | 85.20K | 41.30K | 41.10K |
| Average Diluted Shares Outstanding | 1.04M | 156.70K | 85.20K | 41.30K | 41.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |